Synergistic antitumor effects of dasatinib and oxaliplatin in gastric cancer cells
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Synergistic antitumor effects of dasatinib and oxaliplatin in gastric cancer cells
Authors
Keywords
Gastric cancer, Src, Dasatinib, Oxaliplatin, Synergy
Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 72, Issue 1, Pages 35-44
Publisher
Springer Nature
Online
2013-05-27
DOI
10.1007/s00280-013-2166-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study
- (2012) Kjell Magne Tveit et al. JOURNAL OF CLINICAL ONCOLOGY
- The Role of p27 Kip1 in Dasatinib-Enhanced Paclitaxel Cytotoxicity in Human Ovarian Cancer Cells
- (2011) Xiao-Feng Le et al. JNCI-Journal of the National Cancer Institute
- Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
- (2011) Timothy S Maughan et al. LANCET
- Simultaneous siRNA Targeting of Src and Downstream Signaling Molecules Inhibit Tumor Formation and Metastasis of a Human Model Breast Cancer Cell Line
- (2011) Jeffrey D. Bjorge et al. PLoS One
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
- (2010) T.-C. Chou CANCER RESEARCH
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
- (2010) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Identification of c-Src as a Potential Therapeutic Target for Gastric Cancer and of MET Activation as a Cause of Resistance to c-Src Inhibition
- (2010) W. Okamoto et al. MOLECULAR CANCER THERAPEUTICS
- Synergistic Activity of the Src Family Kinase Inhibitor Dasatinib and Oxaliplatin in Colon Carcinoma Cells Is Mediated by Oxidative Stress
- (2009) S. Kopetz et al. CANCER RESEARCH
- Secreted LOXL2 is a novel therapeutic target that promotes gastric cancer metastasis via the Src/FAK pathway
- (2009) Liang Peng et al. CARCINOGENESIS
- Src kinases as therapeutic targets for cancer
- (2009) Lori C. Kim et al. Nature Reviews Clinical Oncology
- Combination of Two but Not Three Current Targeted Drugs Can Improve Therapy of Chronic Myeloid Leukemia
- (2009) Natalia L. Komarova et al. PLoS One
- Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie
- (2008) Salah-Eddin Al-Batran et al. JOURNAL OF CLINICAL ONCOLOGY
- Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
- (2008) David Cunningham et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now